Nabil Ismaili, Director of Medical Oncology and Radiotherapy Department at Mohammed VI University of Sciences and Health, shared on LinkedIn:
“Thrilled to share that our editorial “Emergence of HER2 as a Key Biomarker and Therapeutic Target in Advanced Urothelial Carcinoma” was published in the World Journal of Clinical Oncology on July 24, 2026!
This paper highlights the critical findings by Huang and He on HER2 overexpression in upper tract urothelial carcinoma and contextualizes them within the paradigm-shifting results of the phase 3 RC48-C016 trial, now published in The New England Journal of Medicine.
Key takeaway
The combination of disitamab vedotin (anti-HER2 ADC) plus toripalimab (anti-PD-1) has demonstrated:
- Median PFS: 13.1 vs 6.5 months (HR=0.36)
- Median OS: 31.5 vs 16.9 months (HR=0.54)
- ORR: 76.1% vs 50.2%
- Favorable safety profile
With nearly 50% of upper tract UC tumors expressing HER2, a substantial subset of patients may now benefit from this biomarker-driven therapy. The era of precision oncology in urothelial carcinoma has truly arrived.
Grateful for the opportunity to contribute to this rapidly evolving field.”
Title: Emergence of HER2 as a Key Biomarker and Therapeutic Target in Advanced Urothelial Carcinoma
Author: Nabil Ismaili
Read also “ctDNA Monitoring During EV ± Pembrolizumab in Advanced Urothelial Carcinoma” on OncoDaily.
